Literature DB >> 32419917

Twitter debate: controversies in functional gastrointestinal disorders.

James Maurice1, Monika M Widlak2, Anton V Emmanuel3.   

Abstract

The new 'Controversies In…' series for the Frontline Gastroenterology Twitter debates addressed the difficult area of functional gastrointestinal disorders, facilitated by the former editor-in-chief Anton Emmanuel. Key topics discussed included distinguishing functional dyspepsia from genuine gastroparesis, when we should investigate for bile acid malabsorption, the current treatments for constipation-predominant irritable bowel syndrome and, importantly, how to manage consultations with complex patients presenting with functional bowel disease. The debate generated over a million impressions on twitter and this article aims to summarise the key educational points from the event. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  functional bowel disorder; gastroparesis; irritable bowel syndrome

Year:  2019        PMID: 32419917      PMCID: PMC7223289          DOI: 10.1136/flgastro-2019-101246

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  13 in total

1.  Functional dyspepsia, delayed gastric emptying, and impaired quality of life.

Authors:  N J Talley; G R Locke; B D Lahr; A R Zinsmeister; G Tougas; G Ligozio; M A Rojavin; J Tack
Journal:  Gut       Date:  2005-12-01       Impact factor: 23.059

2.  Intending to Treat Patients With Irritable Bowel Syndrome With Cognitive-Behavioral Therapy.

Authors:  Alexander C Ford
Journal:  Gastroenterology       Date:  2018-09-18       Impact factor: 22.682

3.  Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome.

Authors:  Heidi M Staudacher; Miranda C E Lomer; Jacqueline L Anderson; Jacqueline S Barrett; Jane G Muir; Peter M Irving; Kevin Whelan
Journal:  J Nutr       Date:  2012-06-27       Impact factor: 4.798

4.  Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome.

Authors:  H M Staudacher; K Whelan; P M Irving; M C E Lomer
Journal:  J Hum Nutr Diet       Date:  2011-05-25       Impact factor: 3.089

Review 5.  Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report.

Authors:  Douglas A Drossman; Jan Tack; Alexander C Ford; Eva Szigethy; Hans Törnblom; Lukas Van Oudenhove
Journal:  Gastroenterology       Date:  2017-12-22       Impact factor: 22.682

6.  Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study.

Authors:  Sofie Ingdam Halkjær; Alice Højer Christensen; Bobby Zhao Sheng Lo; Patrick Denis Browne; Stig Günther; Lars Hestbjerg Hansen; Andreas Munk Petersen
Journal:  Gut       Date:  2018-07-06       Impact factor: 23.059

Review 7.  Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis.

Authors:  Alexander C Ford; Eamonn M M Quigley; Brian E Lacy; Anthony J Lembo; Yuri A Saito; Lawrence R Schiller; Edy E Soffer; Brennan M R Spiegel; Paul Moayyedi
Journal:  Am J Gastroenterol       Date:  2014-06-17       Impact factor: 10.864

8.  Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis.

Authors:  Christopher J Black; Nicholas E Burr; Eamonn M M Quigley; Paul Moayyedi; Lesley A Houghton; Alexander C Ford
Journal:  Gastroenterology       Date:  2018-08-23       Impact factor: 22.682

9.  Randomised controlled trial of mesalazine in IBS.

Authors:  Giovanni Barbara; Cesare Cremon; Vito Annese; Guido Basilisco; Franco Bazzoli; Massimo Bellini; Antonio Benedetti; Luigi Benini; Fabrizio Bossa; Paola Buldrini; Michele Cicala; Rosario Cuomo; Bastianello Germanà; Paola Molteni; Matteo Neri; Marcello Rodi; Alfredo Saggioro; Maria Lia Scribano; Maurizio Vecchi; Giorgio Zoli; Roberto Corinaldesi; Vincenzo Stanghellini
Journal:  Gut       Date:  2014-12-22       Impact factor: 23.059

10.  A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D).

Authors:  Ching Lam; Wei Tan; Matthew Leighton; Margaret Hastings; Melanie Lingaya; Yirga Falcone; Xiaoying Zhou; Luting Xu; Peter Whorwell; Andrew F Walls; Abed Zaitoun; Alan Montgomery; Robin Spiller
Journal:  Gut       Date:  2015-03-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.